Group 1 - The core viewpoint of the article is that Yibai Pharmaceutical (600594) is expected to report a net profit loss of between 285 million yuan and 342 million yuan for the year 2025 [1] - The company anticipates a 14% decline in revenue due to reduced sales of its main products [1] - Although the company's cost expenses are expected to decrease by 18%, the total cost expenses will still exceed revenue, leading to the projected loss [1] Group 2 - The financial department of the company plans to recognize an impairment provision for goodwill between 110 million yuan and 132 million yuan based on preliminary impairment testing results [1] - This impairment provision is expected to further increase the company's losses for the period [1]

Core Viewpoint - Yibai Pharmaceutical (600594.SH) is expected to report a net loss attributable to shareholders of the parent company ranging from -342 million to -285 million yuan for the fiscal year 2025, indicating a significant downturn in financial performance [1] Group 1: Financial Performance - The company's main product sales have decreased, leading to an anticipated revenue decline of 14% [1] - Although the company's cost expenses are expected to decrease by 18%, the total cost expenses will still exceed revenue, resulting in a loss for the period [1] Group 2: Impairment and Accounting - Based on preliminary impairment testing results, the financial department anticipates recognizing goodwill impairment provisions between 110 million and 132 million yuan, which will further increase the company's losses [1]

Core Viewpoint - Yibai Pharmaceutical (600594.SH) is expected to report a net loss attributable to shareholders of the parent company ranging from -342 million to -285 million yuan for the fiscal year 2025, indicating a significant downturn in financial performance [1] Financial Performance - The company's main product sales have decreased, leading to an anticipated revenue decline of 14% [1] - Although the company's cost expenses are expected to decrease by 18%, the total cost expenses will still exceed revenue, resulting in a net loss for the period [1] Impairment and Provisions - Based on preliminary impairment testing results, the financial department anticipates recognizing goodwill impairment provisions between 110 million and 132 million yuan, which will further increase the company's losses [1]

Core Viewpoint - Yibai Pharmaceutical is forecasting a significant net loss for 2025, with expected losses ranging from 285 million to 342 million yuan, indicating ongoing financial challenges for the company [1] Financial Performance - The company anticipates a 14% decline in revenue due to reduced sales of its main products [1] - Despite an expected 18% decrease in costs and expenses, the total costs will still exceed revenue, leading to the projected losses [1]

Core Viewpoint - The company Yibai Pharmaceutical (600594.SH) is expected to report a significant loss in 2025, with projected net profit attributable to shareholders ranging from -342 million to -285 million yuan [1] Financial Performance - The company anticipates a decline in revenue by 14% due to reduced sales of its main products [1] - Despite an expected decrease in costs and expenses by 18%, the total costs will still exceed revenue, leading to the projected losses [1] - The net profit after deducting non-recurring gains and losses is estimated to be between -336 million and -280 million yuan [1]

Financial Performance Forecast - The company expects a net profit attributable to shareholders of the parent company for 2025 to be between -342 million and -285 million RMB, indicating a loss [3]. - The expected net profit after deducting non-recurring gains and losses is projected to be between -336 million and -280 million RMB [4]. - In 2024, the total profit was -332.52 million RMB, with a net profit attributable to shareholders of -317.22 million RMB [5]. Revenue and Cost Projections - The company anticipates a 14% decline in revenue due to decreased sales of main products, despite a projected 18% decrease in costs [7]. - The company plans to recognize goodwill impairment of 110 million to 132 million RMB, which will further increase the loss [7]. Earnings Forecast and Audit Status - The earnings forecast is based on preliminary calculations and has not been audited by a registered accountant [8]. - The company emphasizes that the forecast data is preliminary and the final audited financial data will be disclosed in the 2025 annual report [9].

Core Viewpoint - Yibai Pharmaceutical announced a profit warning for the fiscal year 2025, expecting a net loss attributable to shareholders of between 285 million to 342 million yuan, indicating a significant deterioration compared to a loss of 317.22 million yuan in the same period last year [1] Financial Performance - The company anticipates a decline in revenue due to reduced sales of its main products [1] - Although costs have decreased, they remain higher than revenue, contributing to the expected losses [1] - The company plans to recognize an impairment provision for goodwill between 110 million to 132 million yuan, which will further exacerbate the losses [1]

Core Viewpoint - Yibai Pharmaceutical (600594) expects to report a net loss attributable to shareholders for the fiscal year 2025, with specific figures yet to be disclosed [1] Financial Performance - The company's financial department has conducted preliminary assessments confirming that operating performance will face losses [1] - Yibai Pharmaceutical will expedite its financial accounting processes and aims to disclose the 2025 performance forecast within the stipulated timeframe [1] - The final financial data will be based on the formally disclosed audited annual report [1]

Group 1 - The company, Guizhou Yibai Pharmaceutical Co., Ltd., expects a net profit attributable to shareholders to be negative for the fiscal year 2025, indicating an anticipated loss in operating performance [1] - The company will adhere to the relevant regulations of the Shanghai Stock Exchange and expedite its financial accounting process to disclose the 2025 annual performance forecast within the stipulated timeframe [1] - Final financial data will be based on the officially disclosed audited annual report for 2025 [1] Group 2 - The announcement emphasizes the importance of accurate and complete information disclosure, with the board of directors ensuring there are no false records or misleading statements [1] - Designated media for information disclosure include Securities Times, Securities Daily, Shanghai Securities Journal, China Securities Journal, and the Shanghai Stock Exchange website [1]

Core Viewpoint - Yibai Pharmaceutical (600594.SH) announced that it expects a negative net profit attributable to shareholders for the fiscal year 2025, indicating an anticipated operational loss for the company in that year [1] Financial Performance - The company’s financial department has conducted preliminary calculations, leading to the expectation of a loss in 2025 [1]